BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more
BioNexus Gene Lab Corp Common stock (BGLC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.181x
Based on the latest financial reports, BioNexus Gene Lab Corp Common stock (BGLC) has a cash flow conversion efficiency ratio of -0.181x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.23 Million) by net assets ($6.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioNexus Gene Lab Corp Common stock - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how BioNexus Gene Lab Corp Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioNexus Gene Lab Corp Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNexus Gene Lab Corp Common stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Dewi Shri Farmindo Tbk
JK:DEWI
|
-0.032x |
|
Truong Long Engineering and Auto JSC
VN:HTL
|
N/A |
|
SEI
BK:SEI
|
0.240x |
|
Absolicon Solar Collector AB Series B
ST:ABSL-B
|
-0.076x |
|
Carmat
PA:ALCAR
|
0.344x |
|
TEMPUS RESOURCES LTD
F:4W0
|
N/A |
|
Hiper Global Ltd
TA:HIPR
|
0.127x |
|
Tissue Repair Ltd
AU:TRP
|
-0.091x |
Annual Cash Flow Conversion Efficiency for BioNexus Gene Lab Corp Common stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of BioNexus Gene Lab Corp Common stock from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.32 Million | $-2.23 Million | -0.268x | -47.24% |
| 2023-12-31 | $9.66 Million | $-1.76 Million | -0.182x | -323.36% |
| 2022-12-31 | $6.67 Million | $544.03K | 0.082x | +6297.18% |
| 2021-12-31 | $7.18 Million | $9.16K | 0.001x | -98.46% |
| 2020-12-31 | $6.66 Million | $552.68K | 0.083x | +142.85% |
| 2019-12-31 | $1.12 Million | $-217.27K | -0.194x | -7.49% |
| 2018-12-31 | $1.52 Million | $-274.08K | -0.180x | -104.77% |
| 2017-12-31 | $94.63K | $357.22K | 3.775x | +492.70% |
| 2016-12-31 | $-1.31K | $-835.00 | 0.637x | -- |